一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> Journal of Controlled Release >>article
Journal of Controlled Release

Journal of Controlled Release

IF: 10.5
Download PDF

Cell selective BCL-2 inhibition enabled by lipid nanoparticles alleviates lung fibrosis

Published:6 May 2024 DOI: 10.1016/j.jconrel.2024.04.055
Rimpy Diwan , Himanshu N. Bhatt , Rui Dong , Igor L. Estevao , Armando Varela-Ramirez , Md Nurunnabi

Abstract

Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease with a high mortality rate due to limited treatment options. Current therapies cannot effectively reverse the damage caused by IPF. Research suggests that promoting programmed cell death (apoptosis) in myofibroblasts, the key cells driving fibrosis, could be a promising strategy. However, inducing apoptosis in healthy cells like epithelial and endothelial cells can cause unwanted side effects. This project addresses this challenge by developing a targeted approach to induce apoptosis specifically in myofibroblasts. We designed liposomes (LPS) decorated with peptides that recognize VCAM-1, a protein highly expressed on myofibroblasts in fibrotic lungs. These VCAM1-targeted LPS encapsulate Venetoclax (VNT), a small molecule drug that inhibits BCL-2, an anti-apoptotic protein. By delivering VNT directly to myofibroblasts, we hypothesize that VCAM1-VNT-LPS can selectively induce apoptosis in these cells, leading to reduced fibrosis and improved lung function. We successfully characterized VCAM1-VNT-LPS for size, surface charge, and drug loading efficiency. Additionally, we evaluated their stability over three months at different temperatures. In vitro and in vivo studies using a bleomycin-induced mouse model of lung fibrosis demonstrated the therapeutic potential of VCAM1-VNT-LPS. These studies showed a reduction in fibrosis-associated proteins (collagen, α-SMA, VCAM1) and BCL-2, while simultaneously increasing apoptosis in myofibroblasts. These findings suggest that VCAM1-targeted delivery of BCL-2 inhibitors using liposomes presents a promising and potentially selective therapeutic approach for IPF.

Substances (12)

Materials
Procduct Name CAS Molecular Formula Supplier Price
ABT-199 1257044-40-8 C45H50ClN7O7S 534 suppliers $12.00-$4766.80
ABT-199 1257044-40-8 C45H50ClN7O7S 534 suppliers $12.00-$4766.80
ABT-199 1257044-40-8 C45H50ClN7O7S 534 suppliers $12.00-$4766.80
ABT-199 1257044-40-8 C45H50ClN7O7S 534 suppliers $12.00-$4766.80
ABT-199 1257044-40-8 C45H50ClN7O7S - Inquiry
ABT-199 1257044-40-8 C45H50ClN7O7S - Inquiry
ABT-199 1257044-40-8 - Inquiry
ABT-199 1257044-40-8 - Inquiry
ABT199 1257044-40-8 - Inquiry
ABT199 1257044-40-8 - Inquiry

Similar articles

IF:4.5

Preparation and evaluation of kojic acid dipalmitate solid lipid nanoparticles

Journal of Drug Delivery Science and Technology F. Mohammadi,?Rashin Giti,etc Published: 28 October 2020
桓仁| 炉霍县| 千阳县| 双城市| 西峡县| 宁晋县| 澜沧| 佛教| 泰来县| 洛宁县| 太白县| 合阳县| 张家界市| 久治县| 黎城县| 台湾省| 黎城县| 靖远县| 类乌齐县| 永城市| 峨边| 平邑县| 阜新市| 璧山县| 江城| 鄂尔多斯市| 郓城县| 白朗县| 兴海县| 葫芦岛市| 祥云县| 陆良县| 鹤山市| 田林县| 洛隆县| 峨眉山市| 嘉兴市| 宁海县| 云霄县| 合肥市| 洞头县|